Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) is set to release its earnings data before the market opens on Tuesday, November 5th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.32) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business’s revenue was up 110.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.02) earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Up 2.6 %

Shares of APLS opened at $27.98 on Friday. The firm has a fifty day moving average price of $32.04 and a 200-day moving average price of $37.70. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The firm has a market capitalization of $3.41 billion, a P/E ratio of -10.21 and a beta of 0.87. Apellis Pharmaceuticals has a 12-month low of $26.28 and a 12-month high of $73.80.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on APLS. JPMorgan Chase & Co. lowered their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Wedbush increased their price objective on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. William Blair assumed coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating on the stock. HC Wainwright dropped their price target on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $85.00 price target on shares of Apellis Pharmaceuticals in a research note on Friday, September 20th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $65.41.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).